Cationic Nanoparticle-Mediated Activation of Natural Killer Cells for Effective Cancer Immunotherapy

Component: Nanoparticle Core; Description: Magnetic nanoparticles (iron oxide) synthesized via thermal decomposition

Component: Coating Layer 1; Description: Polydopamine (PDA) — formed via dopamine self-polymerization; provides catechol groups for conjugation; diameter ~38 nm

Component: Coating Layer 2; Description: Polyethyleneimine (PEI) — cationic polymer; immobilized via Michael addition or Schiff base reaction between catechol groups (PDA) and amine groups (PEI); diameter ~41 nm

Component: Final Nanoparticle; Description: cNPs (cationic nanoparticles) — core-shell structure; ζ-potential: +38 mV (vs. PDA-NPs: −20 mV)

Component: Anionic Control; Description: aNPs — synthesized by succinylation of PEI primary amine groups; ζ-potential: −20 mV

Component: Cell Types; Description: • NK-92MI (human NK cell line)<br>• Primary NK cells (pNK) — purified from human peripheral blood mononuclear cells<br>• MDA-MB-231 (human triple-negative breast cancer cells)

Component: Mouse Model; Description: Athymic nude mice (female, 6 weeks old); orthotopic MDA-MB-231 GFP-Luc xenograft (mammary fat pad)

Component: Administration; Description: Intratumoral injection of NK cells (1×10⁷ cells; 4 times, twice weekly)

Component: Tracking Modality; Description: MRI (T₂-weighted imaging) — cNPs have magnetic core enabling MR contrast

Parameter: In Vitro NK Activation; Details: NK cells treated with cNPs (20 μg/L, 48 h); washed; co-cultured with MDA-MB-231 at E:T = 10:1 for 4 h

Parameter: Cytotoxicity Assays; Details: • CFSE/7AAD staining (flow cytometry)<br>• CD107a degranulation assay<br>• Caspase-3/7 activity (fluorescence)<br>• Cleaved caspase-3 Western blot

Parameter: Live-Cell Imaging; Details: Time-lapse microscopy (6 h, 3 min intervals); engagement rate and contact duration quantified

Parameter: Receptor Expression; Details: Flow cytometry: 18 receptors (chemotaxis, adhesion); focus on CCR4 and CXCR4

Parameter: Signaling Pathways; Details: ERK and p38 MAPK (Western blot)

Parameter: Persistence Study; Details: NK cells treated with cNPs (48 h), then cultured in cNP-free medium for 0-6 days; cytotoxicity measured at each time point; Bio-TEM for intracellular NP distribution

Parameter: In Vivo Tumor Model; Details: MDA-MB-231 GFP-Luc cells injected into mammary fat pad (day 0); NK cell injection on days 12, 16, 20, 23; tumor volume measured; bioluminescence imaging at day 50

Parameter: Controls; Details: • DPBS (no NK cells)<br>• NK-92MI (no cNP treatment)<br>• aNP-treated NK cells (anionic control)<br>• PDA-NP-treated NK cells

Parameter: Sample Sizes; Details: In vitro: ≥3 independent experiments; In vivo: not explicitly stated (typical n=5-8 per group)

Parameter: Statistical Tests; Details: Student's unpaired t-test (two groups); P < 0.05 considered significant

Analysis Category: Nanoparticle Characterization; Methods: DLS (size, zeta potential); SEM/TEM (morphology); FT-IR (chemical bonds); Fluorescamine assay (amine group quantification)

Analysis Category: Cell Viability; Methods: WST assay (NK-92MI cells after NP treatment; >90% viability threshold)

Analysis Category: Cytotoxicity; Methods: CFSE/7AAD flow cytometry; caspase-3/7 fluorescence assay; Western blot (cleaved caspase-3)

Analysis Category: Degranulation; Methods: CD107a-APC staining (flow cytometry)

Analysis Category: Receptor Expression; Methods: Flow cytometry (18 receptors; CCR4, CXCR4 highlighted)

Analysis Category: Signaling Pathways; Methods: Western blot (ERK, p38 MAPK phosphorylation)

Analysis Category: Live-Cell Imaging; Methods: Time-lapse microscopy (Olympus IX83, 40× objective); ImageJ analysis; engagement rate and contact duration

Analysis Category: Intracellular NP Distribution; Methods: Bio-TEM (H-7600, Hitachi) at various time points

Analysis Category: In Vivo Imaging; Methods: Bioluminescence (Pearl Impulse, LI-COR); MRI (Bruker 7.0T ClinScan, T₂-weighted)

Analysis Category: Immunohistochemistry; Methods: Cleaved caspase-3 staining of tumor sections; H&E for toxicity assessment

Parameter: Diameter; PDA-NPs: 38 nm; cNPs (PEI-coated): 41 nm; aNPs (anionic control): Not specified

Parameter: ζ-potential; PDA-NPs: −20 mV; cNPs (PEI-coated): +38 mV; aNPs (anionic control): −20 mV

Parameter: Surface amine groups; PDA-NPs: Low; cNPs (PEI-coated): High (PEI concentration-dependent); aNPs (anionic control): Low (blocked)

Parameter: Colloidal stability; PDA-NPs: Good in various media; cNPs (PEI-coated): Good in various media; aNPs (anionic control): Good

Condition: PDA-NPs (no PEI); Cytotoxicity Increase vs. Control: No increase; Key Finding: Similar to control

Condition: cNPs (low PEI); Cytotoxicity Increase vs. Control: Modest increase; Key Finding: PEI concentration-dependent

Condition: cNPs (high PEI); Cytotoxicity Increase vs. Control: >2-fold increase; Key Finding: Highest cytotoxicity

Condition: aNPs (anionic); Cytotoxicity Increase vs. Control: No increase; Key Finding: Charge-dependent effect

Condition: Primary NK + cNPs; Cytotoxicity Increase vs. Control: Marked increase; Key Finding: Effect not limited to NK-92MI

Parameter: CD107a expression (with target cells); Control NK: Baseline; cNP-Treated NK: >2-fold higher; p-value: P < 0.01

Parameter: Caspase-3/7 activity in targets; Control NK: Low; cNP-Treated NK: Significantly increased; p-value: P < 0.01

Parameter: Cleaved caspase-3 (target cells); Control NK: Low; cNP-Treated NK: Enhanced; p-value: Confirmed by IHC

Receptor: CCR4; Control NK: Low; cNP-Treated NK: Significantly increased; Fold Change: >2-fold

Receptor: CXCR4; Control NK: Low; cNP-Treated NK: Significantly increased; Fold Change: >2-fold

Receptor: Other 16 receptors; Control NK: No significant change; cNP-Treated NK: No significant change; Fold Change: -

Parameter: Engagement rate (% NK forming stable contacts >15 min); Control NK: Low; cNP-Treated NK: Significantly higher; p-value: P < 0.01

Parameter: Contact duration (min); Control NK: Transient; cNP-Treated NK: Prolonged; p-value: P < 0.01

Parameter: Killing outcome; Control NK: Failed to kill over 6 h; cNP-Treated NK: Successful killing; p-value: -

Time in cNP-Free Medium: 0 days (post 48 h treatment); Cytotoxicity vs. Control: Highest

Time in cNP-Free Medium: 2 days; Cytotoxicity vs. Control: Decreased but still elevated

Time in cNP-Free Medium: 4 days; Cytotoxicity vs. Control: Further decreased

Time in cNP-Free Medium: 6 days; Cytotoxicity vs. Control: Still significantly higher than control

Time in cNP-Free Medium: Intracellular cNPs; Cytotoxicity vs. Control: Observed for up to 6 days (Bio-TEM)

Group: DPBS (no NK); Tumor Volume (Day 50): Largest; Bioluminescence: Strongest

Group: NK-92MI (control); Tumor Volume (Day 50): Similar to DPBS; Bioluminescence: Similar to DPBS

Group: cNP-treated NK-92MI; Tumor Volume (Day 50): Significantly smaller; Bioluminescence: Weakest

Group: Tumor inhibition; Tumor Volume (Day 50): cNP-treated NK cells most potent; Bioluminescence: Consistent with volume data

Parameter: In vitro phantom (1% agar); Result: cNP-treated NK cells showed concentration-dependent 1/T₂ signal; control NK showed no signal

Parameter: In vivo (intratumoral injection); Result: T₂-weighted MR signal clearly detectable at tumor site (white arrows)

Parameter: Signal detection; Result: MR-positive area correlated with injected cNP-treated NK cells

Parameter: Body weight change; Result: Similar to untreated control

Parameter: Lung histology (H&E); Result: No significant toxicity observed

1. Mechanism not fully elucidated: While CCR4 and CXCR4 upregulation was observed, the authors acknowledge that "the mechanism of cNPs to enhance the immune responses of NK cells is not associated with the altered expression of receptors that govern NK cell activation and cytotoxicity" for other receptors. The signaling pathways (ERK, p38 MAPK) were not activated, indicating "cNPs activate NK cells by a different mechanism" that remains unclear.

2. Ex vivo activation required: NK cells were treated with cNPs ex vivo before adoptive transfer; the approach does not achieve in vivo NK cell activation (though this may be desirable for cell therapy products).

3. Intratumoral injection route: NK cells were injected intratumorally, not systemically, which may limit translation to metastatic diseases or inaccessible tumors.

4. In vivo tracking not quantified: While MRI of cNP-labeled NK cells was demonstrated, the study did not quantify the number of cells reaching the tumor, biodistribution, or persistence over time in vivo.

5. Limited sample size reporting: The paper states "data from more than three independent experiments" but does not consistently report exact n values or SEM/SD for in vivo experiments.

6. No comparison to cytokine-activated NK cells: The study does not benchmark cNP-treated NK cells against conventional IL-2- or IL-15-activated NK cells in terms of cytotoxicity or persistence.

7. Cytokine secretion not enhanced: The authors note that "secretion of these molecules [perforin, granzyme, TNF-α, IFN-γ] did not change significantly upon cNP treatment" — this is an atypical activation mechanism and may limit certain effector functions.

8. PEI toxicity concerns: PEI is known for cytotoxicity; while the study showed >90% viability at the tested concentration, long-term safety and potential off-target effects of residual PEI were not extensively evaluated.

9. Allogeneic NK cell source: The study uses NK-92MI (a cell line) and primary NK cells; for clinical translation, allogeneic NK cells require careful quality control and potential immunogenicity considerations.

10. No survival endpoint: The study measured tumor volume but did not report survival benefit in treated animals.

11. Confounding effect of nanoparticles on flow cytometry: cNPs could potentially interfere with antibody staining or flow cytometry readouts; controls for this were not explicitly described.

12. Limited receptor panel: While 18 receptors were examined, other potential mechanisms (e.g., changes in lipid raft composition, membrane fluidity, or cytoskeletal reorganization) were not investigated.

Report prepared based on the published ACS Applied Materials & Interfaces article. For full experimental details, supplementary figures, and complete references, please refer to the original publication and accompanying supporting information.